Cross-Over Study of Subcutaneous Study Drug for the Treatment of Patients With Mild to Moderate Asthma
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate if single subcutaneous (SC) doses of PL-3994,
administered to patients with asthma can achieve a clinically meaningful increase in
pulmonary function (Forced Expiratory Volume in one second: FEV1) while maintaining an
acceptable safety profile. The study will characterize the bronchodilator effect, dose and
safety of PL-3994 in a population of moderately severe, stable asthmatics following overnight
withdrawal of beta-2 agonists.